Annuaire du CSM
Mme Valérie VIAL
Technicienne Supérieure - Équipes : Hypoxie Tumorale et Métabolisme - Cellules Souches et Tumeurs du CerveauTel. +377 97 77 44 20
Email : [javascript protected email address]
Thèmes de recherche développés
Publications CSM
-
Exploiting Integrin-αVβ3 to Enhance Radiotherapy Efficacy in Medulloblastoma via Ferroptosis
Gotorbe C, Segui F, Echavidre W, Durivault J, Blanchard T, Vial V, Pagnuzzi-Boncompagni M, Villeneuve R, Amblard R, Garnier N, Ortholan C, Serrano B, Picco V, Pouyssegur J, Vucetic M, Montemagno C
Curr. Oncol. 31, 7390–7402 -
A group of novel VEGF splice variants as alternative therapeutic targets in renal cell carcinoma
Montemagno C, Durivault J, Gastaldi C, Dufies M, Vial V, He X, Ambrosetti D, Kamenskaya A, Négrier S, Bernhard J-C, Borchiellini D, Cao Y, Pagès G
mol 21 Feb 2023, 45 -
Integrin-αvβ3 is a Therapeutically Targetable Fundamental Factor in Medulloblastoma Tumorigenicity and Radioresistance
Echavidre W, Durivault J, Gotorbe C, Blanchard T, Pagnuzzi M, Vial V, Raes F, Broisat A, Villeneuve R, Amblard R, Garnier N, Ortholan C, Faraggi M, Serrano B, Picco V, Montemagno C
Cancer Res Commun 3(12):2483-2496 -
Antiangiogenic Compound Axitinib Demonstrates Low Toxicity and Antitumoral Effects against Medulloblastoma
Pagnuzzi M, Picco V, Vial V, Planas-Bielsa V, Vandenberghe A, Daubon T, Derieppe M-A, Montemagno C, Durivault J, Grépin R, Martial S, Doyen J, Gavard J, Pagès G
Cancers 14(1) : 70 -
Anti-Vascular Endothelial Growth Factor C Antibodies Efficiently Inhibit the Growth of Experimental Clear Cell Renal Cell Carcinomas
Dumond A, Montemagno C, Vial V, Grépin R, Pagès G
Cells 10(5): 1222 -
In vivo monitoring of the therapeutic efficacy of a CXCR1/2 inhibitor with 18F-FDG PET/CT imaging in experimental head and neck carcinoma: A feasibility study
Montemagno C, Serrano B, Durivault J, Nataf V, Mocquot F, Amblard R, Vial V, Ronco C, Benhida R, Dufies M, Faraggi M, Pagès G
Biochem Biophys Rep 27: 101098 -
Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma
Dumond A, Brachet E, Durivault J, Vial V, Puszko A K, Lepelletier Y, Montemagno C, Pagnuzzi M, Hermine O, Garbay C, Lagarde N, Montes M, Demange L, Grépin R, Pagès G
J Exp Clinical Cancer Research 40: 33 -
Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5
Giuliano S, Dufies M, Ndiaye P D, Viotti J, Borchiellini D, Parola J, Vial V, Cormerais Y, Ohanna M, Imbert V, Chamorey E, Rioux-Leclercq N, Savina A, Ferrero J-M, Mograbi B, Pagès G
Theranostics 9(4): 1181-1199 -
AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity
Brolih S, Parks S, Vial V, Durivault J, Mostosi L, Pouyssegur J, Pagès G, Picco V
BMC Cancer 18(1): 249 -
The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5)
Cormerais Y, Massard P-A, Vucetic M, Giuliano S, Tambutté E, Durivault J, Vial V, Endou H, Wempe M F, Parks S, Pouyssegur J
J Biol Chem 293(8): 2877-2887 -
Disrupting glucose-6-phosphate isomerase fully suppresses the ‘Warburg effect’ and activates OXPHOS with minimal impact on tumor growth except in hypoxia
Cunha de Padua M, Delodi G, Vucetic M, Durivault J, Vial V, Bayer P, Noleto G, Mazure N, Zdralevic M, Pouyssegur J
Oncotarget 8(50): 87623-87637 -
Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas.
Dufies M, Giuliano S, Ambrosetti D, Claren A, Ndiaye P D, Mastri M, Moghrabi W, Cooley L S, Ettaiche M, Chamorey E, Parola J, Vial V, Lupus-Plesu M, Bernhard J C, Ravaud A, Borchiellini D, Ferrero J M, Bikfalvi A, Ebos J M, Khabar K S, Grépin R, Pagès G
Cancer Res 77(5): 1-15